Why consider treatment in China for Lymphoma?

China is a global leader in CAR-T cell therapy research, with over 700 active clinical trials. The country has approved domestic CD19 and BCMA CAR-T products that offer cutting-edge treatment at a fraction of the cost in Western countries. Additionally, Chinese oncology centers have extensive experience in managing lymphoma, combining advanced immunotherapy with traditional approaches, and often have shorter waiting times for treatment initiation.